% | $
Quotes you view appear here for quick access.

Chelsea Therapeutics Internatio Message Board

  • jk4763 jk4763 Jun 21, 2012 8:02 AM Flag

    why gap up ?

    i dont know of any news..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Chelsea Therapeutics: Phase 3 Data Show 'Clear Efficacy' of Northera in Patients with Neurogenic OH 06/21 07:03 AM

    • Probably related to news. CHTP is presenting data at the Movement Disorders Society annual congress. The headline is about efficacy shown in combined data from 301 and 302.

      While this sounds good now, it also sounded good when CHTP presented this same info to the AdCom. And we all know how that turned out.

      You can check the minutes of the Adcom meeting at the FDA site to see that CHTP presented this same argument and data set.

      • 2 Replies to bolin76
      • Bolin--good to see a post from you. That was my reaction, too. Basically a rehashing of already published data. Do you think that presentations at prestigious meetings like this can have any effect on the FDA? Still looks to me like things depend on the FDA's approval of 306B as the second study that they want. And if they approve that, it will be 3rd quarter next year before we could hope for approval. We remain skeptical of the FDA's continued changing of criticisms of Northera. Seems like they have just been looking for something. Politics? Corruption? Graft? I respect the FDA's purpose, but after attending the Adcom committee, it seems to me that they could have approved Northera while requiring post-marketing studies ongoing.

        I doubt that they do a secondary offering with the stock price this low. Perhaps there will be a pop if the FDA gives approval to 306B. That decision should come pretty soon. The next pop could come toward the end of first quarter next year if 306B shows good results. Sounds like they plan to stretch their money at least until then. I would definitely expect an offering at that time if 306B is a win.

        I don't hold much now, but have been hurt badly along the way. Still feel that this is an excellent drug which can change the lives of patients with NOH.

      • If that's the case then why would they release the same info a second time? Just to get a short term bounce in the share price?

    • 306B trials confirm 301!!! You can't argue with two Phase III trials that show marked patient improvement! Northera will be approved...

    • up 11,45% premarket, smth going on

6.520.00(0.00%)Jun 23 4:00 PMEDT